PRIMARY STUDY
A Placebo-Controlled Trial of Cannabinoid Treatment for Disruptive Behavior in Children and Adolescents with Autism Spectrum Disorder: Effects on Sleep Parameters as Measured by the CSHQ
Key Findings: Although clinical and preclinical studies suggest the endocannabinoid system (ECS) plays a role in the pathology of sleep disorders and Autism spectrum disorder (ASD), this randomized placebo-controlled trial of adolescents with ASD found that administration of cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (THC) at a 20:1 ratio did not improve sleep.
Type of Study: Double Blind Clinical Trial
Study Sample Size: 150
Study Result: Inconclusive
Study Location(s): Israel
Year of Pub: 2022
Cannabinoids Studied: Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH), 2-Arachidonoyl Glycerol (2-AG), Cannabinoid (unspecified)
Phytocannabinoid Source: Cannabis Flower derived
Chemotype: Chemotype II, Chemotype III
Receptors Studied: CB1, CB2, GPCR 55, TRPV1, PPAR - Gamma
Ligands Studied: GABA, Serotonin
